ArticleCrohn's & colitis 3602020
A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease.
Article in Crohn's & colitis 360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps.Journal of managed care & specialty pharmacy · 2025Article
- Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.Journal of clinical medicine · 2024Article
- Approach to loss of response to advanced therapies in inflammatory bowel disease.World journal of gastroenterology · 2024Review
- Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.Journal of clinical medicine · 2024Review
- Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.Frontiers in medicine · 2023Article
- Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.Inflammatory bowel diseases · 2022Article
- Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies.Journal of clinical medicine · 2022Review
- Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease.Crohn's & colitis 360 · 2022Article
- Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.Therapeutic advances in gastroenterology · 2022Article
- How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundUstekinumab was approved for moderate and severe Crohn's disease (CD) in 2016, but little is known about long-term outcomes.
methodsA retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Bradshaw Index (HBI), Short Inflammatory Bowel Disease (SIBDQ), and endoscopy outcomes were collected prospectively.
resultsNinety-six patients received ustekinumab, resulting in improvement in CRP, HBI, and SIBDQ scores with 68% endoscopic improvement/remission. Thirty-four patients underwent reinduction, resulting in improved HBI and CRP.
conclusionsUstekinumab in refractory CD results in significant clinical and endoscopic improvement and reinduction may be a viable option to recapture response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.